A Massachusetts-based company that manufactures APIs closed its Series A and B fundraising, with J&J among the list of investors. Now, the company is announcing another $49 million loan to help boost operations.Entrinsic Bioscience — or EBS — expects to use the loan to fund programs for GI, airway and skin diseases. CEO Stephen Gatto called these programs a “blueprint for serial innovation” in a press release.
The company boasts that it was the first to discover patented combinations of small-molecule amino acids that can modulate targeted epithelial transmembrane proteins through cell signaling. Its first commercialized product is enterade advanced oncology formula, a sugar-free medical food that can help manage side effects from chemotherapy, such as nausea, diarrhea and weight maintenance.